The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000806369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/06/2026
Date registered
Help: Date registered
6/07/2026
Date last updated
Help: Date last updated
7/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
6/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Study in Healthy Adults Comparing a Recombinant Polio Vaccine (rPV) With the IPOL Vaccine to Assess Safety, Immune Response, and Vaccine Reactions.
Scientific title
A Phase 1, double-blinded, Randomized, Active Controlled, Clinical Trial to assess the reactogenicity, safety and Immunogenicity of a recombinant poliomyelitis vaccine (rPV) in comparison with IPOL vaccine in healthy adults.
Additional trial identifiers [1] 317168 0
SII-rPV-01
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Poliovirus 341749 0
Condition category
Condition code
Public Health 337823 337823 0 0
Other public health
Infection 338602 338602 0 0
Other infectious diseases
Neurological 338603 338603 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Investigational vaccine : Recombinant Poliomyelitis Vaccine (rPV)
Dose: 0.5mL once only
Duration of treatment: Vaccine administered once only
Mode of Delivery: Intramuscular injection
The vaccine will be administered by the study doctor or a registered study nurse.
Intervention code [1] 334283 0
Treatment: Drugs
Description of the comparator or control
Comparator vaccine: Inactivated Poliomyelitis Vaccine (IPOL)
Dose: 0.5mL once only
Duration of treatment: Vaccine administered once only
Mode of Delivery: Intramuscular injection
The vaccine will be administered by the study doctor or a registered study nurse.
Control group
Active

Outcomes
Primary outcome [1] 345650 0
To assess the reactogenicity and safety of a single dose of rPV vaccine in comparison with a single dose of IPOL vaccine in healthy adults aged 18 to 60 years. This will be assessed as a composite outcome.
Timepoint [1] 345650 0
The time points for assessment are within 30 minutes, during the 7 day follow-up period and during the 30 days follow-up period.
Secondary outcome [1] 462675 0
To assess immune response against poliomyelitis (Types 1, 2 and 3) 30 days after vaccination with rPV compared to IPOL in healthy adults aged 18 to 60 years.
Timepoint [1] 462675 0
Ist blood sample to take place Pre-dose and at end of study Day 30.

Eligibility
Key inclusion criteria
- Healthy Volunteers aged between 18 to 60 years inclusive.
- Good physical and mental health based on medical history, physical examination, clinical laboratory, electrocardiogram (ECG), and vital signs, as judged by the Investigator.
- Participants must refrain from strenuous exercise within 96 hours (4 days) prior to Screening, Day 1, Day 8, and Day 30..
- Willing and able to comply with restrictions of nicotine (i.e., tobacco and nicotine products) use throughout the study is not permitted from within 48 hours (2 days) prior to Screening, from Day 1 until Day 8, and within 48 hours (2 days) prior to the end of study visit.
- Participants must agree to use highly effective contraception from Day 1 until 90 days after the last study visit.
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
- History of Polio
- Any vaccination received 30 days before Screening and Day 30
- Pregnant or lactating females
- BMI >35.0kg/m2
- History of alcohol abuse or drug addiction
- Have received any polio vaccines within 6 months prior to screening.
- History of major surgeries
- History of receipt of a blood transfusion, other blood products, or immunoglobulins in 3 months prior to study vaccination
- any confirmed or suspected congenital or acquired immunosuppressive or immunodeficient condition.
- Positive drug and/or alcohol screen

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The randomisation code will be provided to the unblinded site pharmacist for dispensing purposes and kept in the pharmacy. Individual code break envelopes will be provided for all participants. Each sealed envelope containing the randomisation code will be kept in a locked restricted area.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomisation list for study vaccine assignment.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment postcode(s) [1] 45941 0
3000 - Melbourne

Funding & Sponsors
Funding source category [1] 321753 0
Commercial sector/Industry
Name [1] 321753 0
Serum Institute of India Pvt, Ltd
Country [1] 321753 0
India
Primary sponsor type
Commercial sector/Industry
Name
Serum Institute of India
Address
Country
India
Secondary sponsor category [1] 324956 0
None
Name [1] 324956 0
Address [1] 324956 0
Country [1] 324956 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320298 0
Bellberry Human Research Ethics Committee J
Ethics committee address [1] 320298 0
Ethics committee country [1] 320298 0
Australia
Date submitted for ethics approval [1] 320298 0
22/04/2026
Approval date [1] 320298 0
04/06/2026
Ethics approval number [1] 320298 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150006 0
Dr Gail Cross
Address 150006 0
Doherty Clinical Trials - 2 St Andrews Pl, Melbourne Victoria 3002
Country 150006 0
Australia
Phone 150006 0
+61 03 9970 4200
Fax 150006 0
Email 150006 0
Contact person for public queries
Name 150007 0
Nicola Byrne
Address 150007 0
Doherty Clinical Trials - 2 St Andrews Pl, Melbourne, Victoria 3002
Country 150007 0
Australia
Phone 150007 0
+61 03 9970 4200
Fax 150007 0
Email 150007 0
Contact person for scientific queries
Name 150008 0
Gail Cross
Address 150008 0
Doherty Clinical Trials - 2 St Andrews Pl, Melbourne, Victoria 3002
Country 150008 0
Australia
Phone 150008 0
+61 03 9970 4200
Fax 150008 0
Email 150008 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Anyone
Conditions for requesting access:
• No requirements
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• May be requested in any format s well as emailing the PI [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.